Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Hepatology

• Publication date

  2014-05-01

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1002/hep.26695PMID 23959503
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Innate immunity: Caspase 8 prevents inflammasome activation

  2013cited by this paper
• Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH

  2013cited by this paper
• PDX-1/Hes-1 interactions determine cholangiocyte proliferative response to injury in rodents: possible implications for sclerosing cholangitis.

  2013cited by this paper
• Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity

  2012cited by this paper
• Inflammasomes in liver diseases.

  2012cited by this paper
• Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases

  2012cited by this paper
• Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.

  2012cited by this paper
• Toll-like receptor 2-mediated intestinal injury and enteric tumor necrosis factor receptor I contribute to liver fibrosis in mice.

  2012cited by this paper
• IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice.

  2012cited by this paper
• Innate Immunity and Alcoholic Liver Disease

  2012cited by this paper
• Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease.

  2012cited by this paper
• Effects of bile duct ligation and cholic acid treatment on fatty liver in two rat models of non-alcoholic fatty liver disease.

  2012cited by this paper
• Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis.

  2012cited by this paper
• Gut microbiome, obesity, and metabolic dysfunction.

  2011cited by this paper
• Hepatocellular carcinoma.

  2011cited by this paper
• Intestinal epithelial cells as producers but not targets of chronic TNF suffice to cause murine Crohn-like pathology

  2011cited by this paper
• Non‐alcoholic steatohepatitis‐induced fibrosis: Toll‐like receptors, reactive oxygen species and Jun N‐terminal kinase

  2011cited by this paper
• From the metabolic syndrome to NAFLD or vice versa?

  2010cited by this paper
• Bile Acids as Regulators of Hepatic Lipid and Glucose Metabolism

  2010cited by this paper
• Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C

  2010cited by this paper
• Obesity, Metabolic Syndrome, and Microbiota: Multiple Interactions

  2010cited by this paper
• Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease

  2009cited by this paper
• CCR1 and CCR5 promote hepatic fibrosis in mice.

  2009cited by this paper
• The core gut microbiome, energy balance and obesity

  2009cited by this paper
• High-fat diet determines the composition of the murine gut microbiome independently of obesity.

  2009cited by this paper
• A core gut microbiome in obese and lean twins

  2008cited by this paper
• Reduced nicotinamide adenine dinucleotide phosphate oxidase mediates fibrotic and inflammatory effects of leptin on hepatic stellate cells

  2008cited by this paper
• Gene expression profiles during hepatic stellate cell activation in culture and in vivo.

  2007cited by this paper
• Endotoxin- and D-galactosamine-induced liver injury improved by the administration of Lactobacillus, Bifidobacterium and blueberry.

  2007cited by this paper
• TLR4 enhances TGF-beta signaling and hepatic fibrosis.

  2007cited by this paper
• Microbial ecology: Human gut microbes associated with obesity

  2006cited by this paper
• Protective role of supplement with foreign Bifidobacterium and Lactobacillus in experimental hepatic ischemia‐reperfusion injury

  2006cited by this paper
• Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms

  2005cited by this paper
• Nonalcoholic fatty liver disease

  2005cited by this paper
• Endotoxin from various gram-negative bacteria has differential effects on function of hepatic cytochrome P450 and drug transporters.

  2005cited by this paper
• The gut microbiota as an environmental factor that regulates fat storage.

  2004cited by this paper
• Bacterial translocation of enteric organisms in patients with cirrhosis.

  2001cited by this paper
• Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.

  2001cited by this paper
• Nonalcoholic fatty liver disease.

  1986cited by this paper
• Hepatocellular carcinoma.

  1986cited by this paper

• [An intestinal microbiotal bacteria involved in the hepatic encephalopathy of patients with cirrhosis].

  2026cites this paper
• The silent threats on plate: health impacts of established and emerging foodborne toxins and contaminants

  2026cites this paper
• Modulation of gut microbiota and its metabolite Equol by Huaier granule suppresses hepatocellular carcinoma via the gut-liver axis

  2026cites this paper
• Intestinal Bacterial Dysbiosis and Liver Fibrosis in Mice Through Gut‐Liver Axis and NLRP3 Inflammatory Pathway Caused by Fine Particulate Matter

  2025cites this paper
• Alteration of the intestinal microbiota associated with the development of nonalcoholic steatohepatitis and sarcopenia in SHRSP5/Dmcr.

  2025cites this paper
• Intestinal NLRP3 Deficiency Exacerbates MASLD in Male Mice via Reduced Butyrate Production

  2025cites this paper
• FAM3B activates hepatic stellate cells to accelerate hepatic fibrosis by promoting glucose metabolism.

  2025cites this paper
• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes

  2025cites this paper
• Early portal hypertension in metabolic dysfunction-associated steatotic liver disease: a concise review

  2025cites this paper
• Peptidoglycan isolated from the fruit of Lycium barbarum alleviates liver fibrosis in mice by regulating the TGF-β/Smad7 signaling and gut microbiota

  2025cites this paper
• Network pharmacology-guided investigation of Fuzheng Yanggan Huaxian decoction in a CCL4-induced hepatic fibrosis mouse model: involvement of the TLR4-MAPK/NF-κB signaling axis and intestinal barrier.

  2025cites this paper
• The impact of sleeve gastrectomy on MASH development by regulating the composition of gut microbiota and metabolic homeostasis.

  2025cites this paper
• Dual GIP and GLP-1 receptor agonist tirzepatide alleviates hepatic steatosis and modulates gut microbiota and bile acid metabolism in diabetic mice.

  2025cites this paper
• Arjunolic acid from Cyclocarya paliurus as a pleiotropic phytochemical effectively counteracts the "multiple parallel hits" in non-alcoholic fatty liver disease.

  2025cites this paper
• Is light-to-moderate alcohol drinking associated with the onset of metabolic dysfunction-associated steatotic liver disease in a Chinese cohort?

  2025cites this paper
• Rivaroxaban alleviates hepatic sinusoidal obstruction syndrome in mice by modulating the gut microbiota and inhibiting the PI3K/Akt signaling pathway

  2025cites this paper
• Octenyl Succinic Anhydride Starch Alleviates Alcoholic Liver Disease by Modulating Gut Microbiota and Metabolism

  2025cites this paper
• Macronutrient Modulation in Metabolic Dysfunction-Associated Steatotic Liver Disease—the Molecular Role of Fatty Acids compared with Sugars in Human Metabolism and Disease Progression

  2025cites this paper
• Excessive dietary fat and fructose enhance hepatic lipogenesis and impair mitochondrial dynamics to cause MASLD in C57BL/6 mice.

  2025cites this paper
• Full-length 16S rRNA Sequencing Reveals Gut Microbiome Signatures Predictive of MASLD in children with obesity

  2025cites this paper
• In Vitro, In Vivo, and In Silico Investigation of Synbiotic-Mediated Activation of PPAR-α Curtails Nonalcoholic Steatohepatitis (NASH) in Wistar Rats by Inhibiting PNPLA3/SREBP1-c Lead Inflammatory Injury of Hepatic Cells

  2025cites this paper
• Liver Fibrosis and Risk of Incident Dementia in the General Population: Systematic Review With Meta‐Analysis

  2025cites this paper
• Critical Role of Cholic Acid in the Development of iHFC Diet-induced MASH in TSNO Mice

  2025cites this paper
• Protection against fibrosis by a bacterial consortium in metabolic dysfunction-associated steatohepatitis and the role of amino acid metabolism

  2024cites this paper
• Gut phageome in Mexican Americans: a population at high risk for metabolic dysfunction-associated steatotic liver disease and diabetes

  2024cites this paper
• Sex and Gender Differences in Liver Fibrosis: Pathomechanisms and Clinical Outcomes

  2024cites this paper
• Antibiotic effects on gut microbiota modulate diet‐induced metabolic dysfunction‐associated steatohepatitis development in C57BL/6 mice

  2024cites this paper
• Metabolic disorders, inter-organ crosstalk, and inflammation in the progression of metabolic dysfunction-associated steatotic liver disease.

  2024cites this paper
• Sheng-Jiang powder ameliorates NAFLD via regulating intestinal microbiota in mice

  2024cites this paper
• Gut microbiota and metabolic biomarkers in metabolic dysfunction–associated steatotic liver disease

  2024cites this paper
• The association between liver fibrosis score and incident dementia: A nationwide retrospective cohort study

  2024cites this paper
• Assessing the Therapeutic Potential of Fecal Microbiota Transplantation in Steatotic Liver Disease: Current Insights and Future Pathways

  2024cites this paper
• This Is What Metabolic Dysfunction–Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol

  2024cites this paper
• Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets

  2024influential citation
• Impacts of liver macrophages, gut microbiota, and bile acid metabolism on the differences in iHFC diet-induced MASH progression between TSNO and TSOD mice

  2024cites this paper
• Gut–Liver Axis Dysregulation in Portal Hypertension: Emerging Frontiers

  2024cites this paper
• The role of macrophages in liver fibrosis: composition, heterogeneity, and therapeutic strategies

  2024cites this paper
• Novel therapeutic approaches based on the pathological role of gut dysbiosis on the link between nonalcoholic fatty liver disease and insulin resistance.

  2023cites this paper
• Glaucocalyxin A attenuates carbon tetrachloride‐induced liver fibrosis and improves the associated gut microbiota imbalance

  2023cites this paper
• Maternal Betaine Supplementation Mitigates Maternal High Fat Diet-Induced NAFLD in Offspring Mice through Gut Microbiota

  2023cites this paper
• Roles of human gut microbiota in liver cirrhosis risk: a two-sample mendelian randomization study.

  2023cites this paper
• Ganoderma lucidum ethanol extracts ameliorate hepatic fibrosis and promote the communication between metabolites and gut microbiota g_Ruminococcus through the NF-κB and TGF-β1/Smads pathways.

  2023cites this paper
• Nonalcoholic Fatty Liver Disease and the Intestinal Microbiome: An Inseparable Link

  2023cites this paper
• Liver complications of total parenteral nutrition: the latest therapeutic strategies

  2023cites this paper
• Gentiopicroside improves high-fat diet-induced NAFLD in association with modulation of host serum metabolome and gut microbiome in mice

  2023cites this paper
• Application of Mendelian randomization to assess host gene–gut microbiota correlations in patients with esophageal cancer

  2023cites this paper
• Gut Dysbiosis and Blood-Brain Barrier Alteration in Hepatic Encephalopathy: From Gut to Brain

  2023cites this paper
• Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling

  2023cites this paper
• Study on the Diversity of Oral Microflora in Patients with Primary Hepatic Carcinoma

  2023cites this paper
• Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key

  2023cites this paper
• Adlercreutzia equolifaciens Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease

  2023cites this paper
• Monkfish (Lophius litulon) Peptides Ameliorate High-Fat-Diet-Induced Nephrotoxicity by Reducing Oxidative Stress and Inflammation via Regulation of Intestinal Flora

  2022cites this paper
• MAFLD under the lens: the role of gut microbiota

  2022cites this paper
• The gut microbiota–bile acid axis: A potential therapeutic target for liver fibrosis

  2022cites this paper
• Antioxidative Self-Assembling Nanoparticles Attenuate the Development of Steatohepatitis and Inhibit Hepatocarcinogenesis in Mice

  2022cites this paper
• Salidroside in the Treatment of NAFLD/NASH

  2022cites this paper
• Research Progress of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease

  2022cites this paper
• Better detoxifying effect of ripe forsythiae fructus over green forsythiae fructus and the potential mechanisms involving bile acids metabolism and gut microbiota

  2022cites this paper
• Sex-Dependent Hepatoprotective Role of IL-22 Receptor Signaling in Non-Alcoholic Fatty Liver Disease-Related Fibrosis

  2022cites this paper
• Probiotic Bacillus Alleviates Oxidative Stress-Induced Liver Injury by Modulating Gut-Liver Axis in a Rat Model

  2022cites this paper
• The Role of the Intestinal Microbiota in Nonalcoholic Steatohepatitis

  2022cites this paper
• Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice

  2022cites this paper
• Effects of dietary palygorskite supplementation on the growth performance, oxidative status, immune function, intestinal barrier and cecal microbial community of broilers

  2022cites this paper
• Ficus hirta Vahl. Ameliorates Nonalcoholic Fatty Liver Disease through Regulating Lipid Metabolism and Gut Microbiota

  2022cites this paper
• Gut Microbiota and Metabolic Diseases

  2022cites this paper
• Fufang Zhenzhu Tiaozhi Capsule Prevents Intestinal Inflammation and Barrier Disruption in Mice With Non-Alcoholic Steatohepatitis

  2022cites this paper
• Global Microbiota‐Dependent Histone Acetylation Patterns Are Irreversible and Independent of Short Chain Fatty Acids

  2021cites this paper
• Perinatal High-Salt Diet Induces Gut Microbiota Dysbiosis, Bile Acid Homeostasis Disbalance, and NAFLD in Weanling Mice Offspring

  2021cites this paper
• Metabolic-associated Fatty Liver Disease as Assessed by the Fatty Liver Index Among Migrant and Non-migrant Ghanaian Populations

  2021cites this paper
• Intestinal Fibrosis and Gut Microbiota: Clues From Other Organs

  2021cites this paper
• Partially hydrolyzed guar gum attenuates non-alcoholic fatty liver disease in mice through the gut-liver axis

  2021cites this paper
• Water soluble dietary fiber from walnut meal as a prebiotic in preventing metabolic syndrome

  2021cites this paper
• The interaction between the gut microbiota and dietary carbohydrates in nonalcoholic fatty liver disease

  2021cites this paper
• Hepatic microbiome in healthy lean and obese humans

  2021cites this paper
• The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD.

  2021cites this paper
• Research Advances in Protective Effects of Ursolic Acid and Oleanolic Acid Against Gastrointestinal Diseases.

  2021cites this paper
• Network Pharmacology-Based Study on the Molecular Biological Mechanism of Action for Qingdu Decoction against Chronic Liver Injury

  2021cites this paper
• Epigallocatechin Gallate Can Protect Mice From Acute Stress Induced by LPS While Stabilizing Gut Microbes and Serum Metabolites Levels

  2021cites this paper
• Ursolic acid reverses liver fibrosis by inhibiting NOX4/NLRP3 inflammasome pathways and bacterial dysbiosis

  2021cites this paper
• An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents

  2021cites this paper
• Multiple bacteria associated with the more dysbiotic genitourinary microbiomes in patients with type 2 diabetes mellitus

  2021cites this paper
• Bacterial and eukaryotic extracellular vesicles and non-alcoholic fatty liver disease: new players in the gut-liver axis?

  2021cites this paper
• Pyroptosis: Mechanisms and Links with Fibrosis

  2021cites this paper
• The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for Cancer

  2021cites this paper
• Fecal Microbiota Transplant from Human to Mice Gives Insights into the Role of the Gut Microbiota in Non-Alcoholic Fatty Liver Disease (NAFLD)

  2021cites this paper
• Gut microbiota and related metabolites in the pathogenesis of nonalcoholic steatohepatitis and its resolution after bariatric surgery

  2021cites this paper
• Gut microbiome in liver pathophysiology and cholestatic liver disease

  2021cites this paper
• Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases

  2021cites this paper
• Traditional Chinese Medicine Ganshuang Granules Attenuate CCl4‐Induced Hepatic Fibrosis by Modulating Gut Microbiota

  2021cites this paper
• Cross‐linkage between bacterial taxonomy and gene functions: a study of metagenome‐assembled genomes of gut microbiota in adult non‐alcoholic fatty liver disease

  2021cites this paper
• Probiotics and Cancer

  2021cites this paper
• Extra- and Intra-Cellular Mechanisms of Hepatic Stellate Cell Activation

  2021cites this paper
• Gut Microbiome and Cancer

  2021cites this paper
• Gut-liver axis modulation in fructose-fed mice: a role for PPAR-alpha and linagliptin.

  2020cites this paper
• Lactobacillus casei YRL577 combined with plant extracts reduce markers of non-alcoholic fatty liver disease in mice

  2020cites this paper
• Characteristics of three microbial colonization states in the duodenum of the cirrhotic patients.

  2020cites this paper
• Lactobacillus casei YRL577 ameliorates markers of non-alcoholic fatty liver and alters expression of genes within the intestinal bile acid pathway

  2020cites this paper
• Effects of Gut Metabolites and Microbiota in Healthy and Marginal Livers Submitted to Surgery

  2020cites this paper
• Gut dysbiosis protects against liver injury in autophagy deficient mice by FXR-FGF15 feedback signaling

  2020cites this paper
• DMSO_A_249949 3861..3872

  2020cites this paper